Predictive factors of resistance to trastuzumab as neoadjuvant therapy in women with HER2-positive breast cancer

被引：0
|
作者：
Jinno, Hiromitsu
Sato, Tomomi
Takahashi, Maiko
Hayashida, Tetsu
Hirose, Shigemichi
Kitagawa, Yuko
机构：
[1] Keio Univ, Sch Med, Dept Surg, Tokyo 160, Japan
[2] Keio Univ, Sch Med, Tokyo 160, Japan
[3] Keio Univ, Sch Med, Dept Pathol, Tokyo 160, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 26期
关键词：
D O I：
10.1200/jco.2013.31.26_suppl.168
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
168
引用
下载
收藏
页数：1
相关论文
共 50 条
  • [1] Mechanisms behind trastuzumab resistance as neoadjuvant therapy in HER2-positive operable breast cancer
    Jinno, H.
    Sato, T.
    Hayashida, T.
    Takahashi, M.
    Hirose, S.
    Kitagawa, Y.
    CANCER RESEARCH, 2012, 72
  • [2] Predictive Factors of Response in HER2-Positive Breast Cancer Treated by Neoadjuvant Therapy
    Guiu, S.
    Reynier, M. A. Mouret
    Toure, M.
    Coudert, B.
    JOURNAL OF ONCOLOGY, 2013, 2013
  • [3] Genomic signature of trastuzumab neoadjuvant therapy predictive of patient survival in HER2-positive breast cancer
    Briones, Natalia
    Facista, Salvatore
    Halperin, Rebecca
    Heaton, Paul
    Mahadevan, Daruka
    Hendricks, Wiiliam
    Kim, Suwon
    CANCER RESEARCH, 2019, 79 (13)
  • [4] Trastuzumab-Based Neoadjuvant Therapy in Patients With HER2-Positive Breast Cancer
    Chang, Helena R.
    CANCER, 2010, 116 (12) : 2856 - 2867
  • [5] Neoadjuvant chemotherapy with trastuzumab in HER2-positive breast cancer: pathologic complete response rate, predictive and prognostic factors
    Buzatto, I. P. C.
    Ribeiro-Silva, A.
    Andrade, J. M.
    Carrara, H. H. A.
    Silveira, W. A.
    Tiezzi, D. G.
    BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, 2017, 50 (02)
  • [6] Trastuzumab therapy in HER2-positive, metastatic breast cancer
    Smith, A. D.
    Guilbert, K.
    Lister, D.
    Streilein, S.
    Bourrier, V. C.
    Lozar, B.
    Navaratnam, S.
    Harding, G. A.
    Pitz, M. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [7] Overcoming trastuzumab resistance in HER2-positive breast cancer using combination therapy
    Derakhshani, Afshin
    Rezaei, Zohreh
    Safarpour, Hossein
    Sabri, Morteza
    Mir, Atefeh
    Sanati, Mohammad Amin
    Vahidian, Fatemeh
    Moghadam, Ali Gholamiyan
    Aghadoukht, Ali
    Hajiasgharzadeh, Khalil
    Baradaran, Behzad
    JOURNAL OF CELLULAR PHYSIOLOGY, 2020, 235 (04) : 3142 - 3156
  • [8] Assessing Response to neoadjuvant Taxotere and TrAstuzumab in Nigerian women with HER2-positive breast cancer (ARETTA)
    Ntekim, Atara
    Adeniji-Sofoluwe, Adenike
    Ibraheem, Abiola
    Sowunmi, Anthonia
    Folasire, Ayorinde
    Olajide, Thomas
    Olasehinde, Olalekan
    Komolafe, Akinwunmi
    Lawal, AbdulRazzak
    Omodele, Foluso
    Sanni, Ayodele
    Ajani, Mustapha
    Kotila, Olayinka
    Folorunsho, Sharifat
    Aniagwu, Tonyin
    Alabi, Adewumi
    Popoola, Abiodun
    Asuzu, Chioma
    Daramola, Adetola
    Babalola, Chinedum
    Karrison, Theodore
    Abdulkareem, Fatimah
    Olopade, Olufunmilayo I.
    CANCER RESEARCH, 2023, 83 (05)
  • [9] Assessing response to neoadjuvant docetaxel and trastuzumab in Nigerian women with HER2-positive breast cancer (ARETTA).
    Ntekim, Atara Isaiah
    Adeniji-Sofoluwe, Omoba Temitayo
    Sowunmi, Anthonia
    Folasire, Ayorinde
    Olasehinde, Olalekan
    Lawaal, AbdulRazzak
    Olajide, Thomas
    Omodele, Foluso
    Fatiregun, Omolara A.
    Sanni, Ayodele
    Ajani, Mustapha
    Kotila, Olayinka
    Komolafe, Akinwunmi O.
    Ao, Alabi
    Olaniyi, Popoola Abiodun
    Asuzu, Chioma Christie
    Daramola, Adetola
    Babalola, Chinedum Peace
    Karrison, Theodore
    Olopade, Olufunmilayo I.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [10] Trastuzumab-Deruxtecan in the Therapy of HER2-positive Breast Cancer
    Schmale, Ine
    BREAST CARE, 2021, 16 (03)
12345